LBC
REGN icon

Lawrence B. Cohen’s Regeneron Pharmaceuticals REGN Stock Holding History

Lawrence B. Cohen’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-500
Closed -$224K – 72
2017
Q3 		$224K Sell
500
-100
-17% -$47.6K 0.15% 68
2017
Q2 		$295K Hold
600
– – 0.19% 65
2017
Q1 		$233K Hold
600
– – 0.14% 69
2016
Q4 		$220K Buy
+600
New +$228K 0.13% 70

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

Lawrence B. Cohen's REGN Position: Q4 2017 in Review

Lawrence B. Cohen sold out of Regeneron Pharmaceuticals (REGN) in Q4 2017, closing a stake of 500 shares — an estimated $224K sold.

Lawrence B. Cohen first reported a position in REGN in Q4 2016 and held it in 4 quarters. The position peaked at $295K in Q2 2017. 639 funds tracked by Wall St. Rank hold REGN as of Q4 2017.

  • Lawrence B. Cohen reported no remaining Regeneron Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Lawrence B. Cohen sold 500 Regeneron Pharmaceuticals shares in Q4 2017, an estimated $224K.
  • Lawrence B. Cohen first reported a position in Regeneron Pharmaceuticals in Q4 2016 and held it in 4 quarters.
  • Lawrence B. Cohen's Regeneron Pharmaceuticals position peaked at $295K in Q2 2017.
  • 639 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2017.

Based on Lawrence B. Cohen's 13F filing for Q4 2017, filed 6 Feb 2018.